Blood Biomarkers in Cardiovascular Diseases

Cardiovascular diseases (CVDs) continue to pose significant challenges for public health as the leading cause of morbidity and mortality worldwide. Early detection, accurate diagnosis, and effective monitoring of CVDs are crucial for timely intervention and improved patient outcomes. Blood biomarkers are emerging as valuable tools in cardiovascular research, offering a promising avenue for the development of novel diagnostic, prognostic, and therapeutic strategies. These biomarkers provide a dynamic and powerful approach to understanding the spectrum of CVDs and have applications in observational and analytic epidemiology, randomized clinical trials, screening and diagnosis and prognosis. Defined as alterations in the constituents of tissues or body fluids, they offer a means for homogeneous classification of diseases and risk factors, and can extend our knowledge about the underlying pathogenesis of CVDs. Causes of variability in biomarker measurement can be individual- or laboratory-related.

This research topic aims to highlight the latest advancements in the field of blood biomarkers for cardiovascular diseases. It invites original research articles, reviews, and meta-analyses that focus on the discovery, validation, and clinical application of blood biomarkers in various aspects of cardiovascular health and disease. We seek contributions from researchers and clinicians working across disciplines, including but not limited to cardiology, biochemistry, molecular biology, genetics, and epidemiology. Finally, a particular mention will be made for biomarkers and cardiac dysfunction in the setting of stroke.

We welcome submissions addressing a wide range of topics related to biomarkers in cardiovascular diseases, including, but not limited to:

- Novel biomarkers for early detection and diagnosis of CVDs
- Prognostic biomarkers for risk stratification and prediction of clinical outcomes
- Biomarkers for monitoring disease progression and treatment response
- Role of genetic and epigenetic biomarkers in CVD risk assessment
- Identification of biomarkers for specific CVD subtypes or phenotypes
- Biomarkers for assessing cardiovascular health in special populations (e.g., elderly, pediatric, pregnant women)
- Biomarkers for evaluating the efficacy and safety of cardiovascular therapies
- Omics-based approaches in biomarker discovery for CVDs
- Bioinformatics and computational tools for biomarker identification and validation
- Translational research and clinical implementation of biomarkers in cardiovascular medicine